FDA Ruling on Dapoxetine a Setback to J&J's Pipeline, Analysts Say

Drug Industry Daily
KEYWORDS FDA / NDA
A A

The FDA has declared Johnson & Johnson’s (J&J) experimental premature ejaculation (PE) drug dapoxetine “not approvable,” dealing a potentially significant setback to the firm’s pipeline, analysts said.

To View This Article:

Login

Subscribe To Drug Industry Daily